Literature DB >> 6393621

[Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].

W A Fach, H J Becker.   

Abstract

The dose-effect relation and duration of action of 2 mg, 4 mg and 6 mg molsidomine on ischemic ST-segment depression in the exercise-ECG were determined in a randomized and double-blind acute study of 12 patients with confirmed coronary artery disease. With 2 mg molsidomine a significant reduction in the amount of ischemic ST-depression from 18.0 mm to 8.1 mm, 45% of the baseline-figure, resulted. With 6 mg molsidomine a diminuation of the ST-segment depression from 16.2 mm to 6 mm, approximately 40%, was noted. The significant antianginal effect of 2 mg molsidomine lasted at least 3 hours. After 5 hours an effect was seen only in some patients. 4 mg and 6 mg molsidomine still showed a significant reduction of ST-segment depression after 5 hours. A sufficient antianginal efect over 24 hours is only achieved with a 2-mg dose administered 5-6 times or with a 4-6 mg dose applied 4-5 times daily. The most marked fall in blood pressure was noticed after 6 mg molsidomine. On average, the systolic blood pressure fell 41 mm Hg (22%). Orthostatic reactions were not seen. The maximal dose-dependent plasma levels were 15.8 ng/ml, 30.1 ng/ml and 50.0 ng/ml. A definite, reliable clinical effect was seen in some cases from plasma levels above 2 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6393621

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  2 in total

1.  A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.

Authors:  Roger Messin; Tamas Fenyvesi; Fabienne Carreer-Bruhwyler; Jacques Crommen; Patrice Chiap; Philippe Hubert; Claude Dubois; Jean-Pierre Famaey; Joseph Géczy
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

2.  Nitric oxide regulates the calcium current in isolated human atrial myocytes.

Authors:  M Kirstein; M Rivet-Bastide; S Hatem; A Bénardeau; J J Mercadier; R Fischmeister
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.